Short Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Rises By 7.5%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,140,000 shares, a growth of 7.5% from the June 15th total of 1,060,000 shares. Currently, 1.7% of the company’s shares are sold short. Based on an average daily volume of 229,200 shares, the short-interest ratio is currently 5.0 days.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently modified their holdings of the stock. Quarry LP bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $48,000. China Universal Asset Management Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 371.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after purchasing an additional 5,037 shares during the period. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals in the first quarter valued at about $109,000. Jump Financial LLC bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $114,000. Finally, Trexquant Investment LP bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $114,000. 82.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CNTA has been the subject of several recent analyst reports. Morgan Stanley upped their target price on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, June 21st. BMO Capital Markets reiterated an “outperform” rating and issued a $15.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.50.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA traded down $0.41 on Wednesday, hitting $9.52. 306,060 shares of the stock were exchanged, compared to its average volume of 304,456. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.37 and a quick ratio of 10.37. The business’s fifty day moving average is $8.97 and its 200 day moving average is $9.44. Centessa Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $12.45. The company has a market capitalization of $956.57 million, a PE ratio of -6.65 and a beta of 1.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.03. Research analysts anticipate that Centessa Pharmaceuticals will post -1.67 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.